Q7TQF2
Gene name |
Fbxo10 (Gm634) |
Protein name |
F-box only protein 10 |
Names |
|
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:269529 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q7TQF2
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q7TQF2-F1 | Predicted | AlphaFoldDB |
37 variants for Q7TQF2
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3388684001 | 43 | T>I | No | EVA | |
| rs3388682511 | 77 | Q>* | No | EVA | |
| rs3388674508 | 136 | L>P | No | EVA | |
| rs3388679896 | 162 | G>D | No | EVA | |
| rs3388683924 | 176 | T>N | No | EVA | |
| rs3388676053 | 193 | M>L | No | EVA | |
| rs3388675975 | 334 | A>V | No | EVA | |
| rs3388679418 | 360 | D>* | No | EVA | |
| rs3388670991 | 361 | E>G | No | EVA | |
| rs3388671018 | 369 | R>I | No | EVA | |
| rs3388677759 | 373 | Q>H | No | EVA | |
| rs3394188245 | 411 | Q>A | No | EVA | |
| rs27826487 | 471 | V>I | No | EVA | |
| rs3388684009 | 475 | N>I | No | EVA | |
| rs3388685402 | 479 | R>H | No | EVA | |
| rs3388676018 | 481 | R>W | No | EVA | |
| rs3388669865 | 490 | E>D | No | EVA | |
| rs3388683996 | 495 | I>N | No | EVA | |
| rs3388683650 | 517 | L>F | No | EVA | |
| rs3388676021 | 535 | G>D | No | EVA | |
| rs3388685430 | 595 | N>D | No | EVA | |
| rs3388679450 | 598 | G>E | No | EVA | |
| rs3388669813 | 639 | Y>VSDG* | No | EVA | |
| rs3388685415 | 711 | R>G | No | EVA | |
| rs3388674454 | 750 | G>A | No | EVA | |
| rs3388676370 | 750 | G>R | No | EVA | |
| rs3388685425 | 789 | R>L | No | EVA | |
| rs3388662494 | 835 | K>N | No | EVA | |
| rs3388674477 | 839 | H>Y | No | EVA | |
| rs3388669874 | 840 | S>A | No | EVA | |
| rs3388676034 | 846 | I>N | No | EVA | |
| rs3388684523 | 847 | A>E | No | EVA | |
| rs3388674466 | 849 | R>W | No | EVA | |
| rs3388662465 | 908 | L>I | No | EVA | |
| rs3388685387 | 915 | S>Y | No | EVA | |
| rs3388676047 | 926 | A>S | No | EVA | |
| rs3388670979 | 926 | A>V | No | EVA |
No associated diseases with Q7TQF2
1 regional properties for Q7TQF2
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | F-box domain | 32 - 64 | IPR001810 |
1 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
No GO annotations of molecular function
| Name | Definition |
|---|---|
| No GO annotations for molecular function |
4 GO annotations of biological process
| Name | Definition |
|---|---|
| apoptotic process | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. |
| protein ubiquitination | The process in which one or more ubiquitin groups are added to a protein. |
| regulation of apoptotic process | Any process that modulates the occurrence or rate of cell death by apoptotic process. |
| ubiquitin-dependent protein catabolic process | The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of a ubiquitin group, or multiple ubiquitin groups, to the protein. |
| 10 | 20 | 30 | 40 | 50 | 60 |
| METGGLPLEL | WRMILAYLHL | PDLGRCSLVC | RAWYELILSL | DSTRWRQLCL | GCTECRHPNW |
| 70 | 80 | 90 | 100 | 110 | 120 |
| PNQPDVEPES | WREAFKQHYL | ASKTWTKNAL | DLESSICFSL | FRRKKERRTL | SVGPGHEFDS |
| 130 | 140 | 150 | 160 | 170 | 180 |
| LGSALAMASL | YDRIVLFPGV | YEEQGEIILK | VPVEIVGQGK | LGEVALLASI | DQHCSTTRVC |
| 190 | 200 | 210 | 220 | 230 | 240 |
| NLVFMPAWFS | PIMYKTTSGH | IQFDNCNFEN | GHIQVHGPGT | CQVKFCTFKN | THVFLHNVPL |
| 250 | 260 | 270 | 280 | 290 | 300 |
| CMLENCEFVG | SENNCVTVEG | HPSADKNWAY | KYLLGLIKSS | PIFLPAEDHD | FLMSLDLESR |
| 310 | 320 | 330 | 340 | 350 | 360 |
| DQAWSPRTCD | IVIEGSQSPT | SPVCSSPKPG | SKEAEVGSDG | ERVAQTPDSS | DGGLSPSGED |
| 370 | 380 | 390 | 400 | 410 | 420 |
| EDDEQLTYRL | SYQVQGPRPV | LGGSFLGPPL | PGASIQLPSC | LVLNSLHQEL | QKDKEAMALA |
| 430 | 440 | 450 | 460 | 470 | 480 |
| SSVQGCLIRK | CLFRDGKGGV | FVCSYGRAKM | EGNVFRNLTY | AVRCIHNSKI | VMLRNDIYRC |
| 490 | 500 | 510 | 520 | 530 | 540 |
| RASGIFLRLE | GGGLIAGNNI | YHNAEAGVDI | RKKSNPLILC | NQIHHGLRSG | IVVLGNGKGV |
| 550 | 560 | 570 | 580 | 590 | 600 |
| IRNNQIFSNK | EAGIYILYHG | NPIVSGNHIF | KGRAAGIAVN | ENGKGLITEN | VIRENQWGGV |
| 610 | 620 | 630 | 640 | 650 | 660 |
| DIRRGGVPIL | RSNLICFGYS | DGVVVGDEGK | GLIEGNTIYA | NKGCGVWMMS | SSLPHVTSNH |
| 670 | 680 | 690 | 700 | 710 | 720 |
| VSYNGLYGVA | VFSQKDGEFP | GGHGAQENFS | EDGDAILWEA | ELEKEDDPLR | RPITVALVES |
| 730 | 740 | 750 | 760 | 770 | 780 |
| NSINHNGASG | IFVQSSEALQ | VVANVIHANG | DRGITIVQSS | QLTRVANNSI | SCNRQSGVKV |
| 790 | 800 | 810 | 820 | 830 | 840 |
| EFQCKVELRG | NGIYDNRGHG | IITKGDGTAV | VENDIIGNRG | SGLQLLPRSD | TKVLKNRIHS |
| 850 | 860 | 870 | 880 | 890 | 900 |
| FRAYGIAVRG | RVKALVQENI | IFQGKTNKTI | FQQITNNREC | IMQNNKFLVF | KKKSDTWRLV |
| 910 | 920 | 930 | 940 | ||
| NPPARPHLEN | SLRGSSAAHS | GHKVTAMATR | ITARVEGGYH | SNRSIFCTIL |